Cottonwood Capital Advisors LLC Raises Stock Position in Cencora, Inc. (NYSE:COR)

Cottonwood Capital Advisors LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 95.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,750 shares of the company’s stock after acquiring an additional 855 shares during the period. Cottonwood Capital Advisors LLC’s holdings in Cencora were worth $393,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Insight Wealth Strategies LLC boosted its holdings in Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after buying an additional 11,232 shares during the last quarter. Cerity Partners LLC lifted its position in shares of Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock valued at $8,881,000 after acquiring an additional 3,610 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after acquiring an additional 2,928 shares during the last quarter. Portfolio Design Labs LLC purchased a new stake in shares of Cencora during the third quarter worth approximately $1,404,000. Finally, Mackenzie Financial Corp raised its stake in Cencora by 9.9% in the 2nd quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock valued at $18,250,000 after purchasing an additional 7,266 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,187 shares of company stock worth $17,790,912 over the last three months. Insiders own 15.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. Barclays raised their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners dropped their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday. Finally, UBS Group boosted their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $277.00.

Cencora Stock Performance

Shares of Cencora stock opened at $248.45 on Friday. The business’s fifty day simple moving average is $237.51 and its 200-day simple moving average is $234.66. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a market cap of $48.02 billion, a PE ratio of 33.08, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $253.27.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.